About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 729497, 13 pages
http://dx.doi.org/10.1155/2011/729497
Review Article

Aortocaval Fistula in Rat: A Unique Model of Volume-Overload Congestive Heart Failure and Cardiac Hypertrophy

1Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion, IIT, P.O. Box 9649, Haifa 31096, Israel
2Research Unit, Rambam Medical Center, Haifa 31096, Israel
3Department of Vascular Surgery, Rambam Medical Center, Haifa 31096, Israel

Received 5 October 2010; Accepted 9 December 2010

Academic Editor: Oreste Gualillo

Copyright © 2011 Zaid Abassi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Kannel, “Current status of the epidemiology of heart failure,” Current Cardiology Reports, vol. 1, no. 1, pp. 11–19, 1999. View at Scopus
  2. M. Jessup and S. Brozena, “Heart failure,” The New England Journal of Medicine, vol. 348, no. 20, pp. 2007–2018, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Hasenfuss, “Animal models of human cardiovascular disease, heart failure and hypertrophy,” Cardiovascular Research, vol. 39, no. 1, pp. 60–76, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. K. O. Stumpe, H. Solle, H. Klein, and F. Kruck, “Mechanism of sodium and water retention in rats with experimental heart failure,” Kidney International, vol. 4, no. 5, pp. 309–317, 1973. View at Scopus
  5. K. O. Stumpe, B. Reinelt, C. Ressel, H. Klein, and F. Kruck, “Urinary sodium excretion and proximal tubule reabsorption in rats with high output heart failure,” Nephron, vol. 12, no. 4, pp. 261–274, 1974. View at Scopus
  6. A. Hoffman, E. Grossman, and H. R. Keiser, “Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure,” American Journal of Hypertension, vol. 4, no. 7 I, pp. 597–601, 1991. View at Scopus
  7. J. Winaver, A. Hoffman, J. C. Burnett, and A. Haramati, “Hormonal determinants of sodium excretion in rats with experimental high-output heart failure,” American Journal of Physiology, vol. 254, no. 5, pp. R776–R784, 1988. View at Scopus
  8. Z. Abassi, A. Haramati, A. Hoffman, J. C. Burnett, and J. Winaver, “Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure,” American Journal of Physiology, vol. 259, no. 1, pp. R84–R89, 1990. View at Scopus
  9. T. Karram, A. Abbasi, S. Keidar et al., “Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure,” American Journal of Physiology, vol. 289, no. 4, pp. H1351–H1358, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. A. Abassi, S. Brodsky, T. Karram, I. Dobkin, J. Winaver, and A. Hoffman, “Temporal changes in natriuretic and antinatriuretic systems after closure of a large arteriovenous fistula,” Cardiovascular Research, vol. 51, no. 3, pp. 567–576, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. A. Abassi, K. Gurbanov, S. E. Mulroney et al., “Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II,” Circulation, vol. 96, no. 10, pp. 3655–3664, 1997. View at Scopus
  12. S. Brodsky, K. Gurbanov, Z. Abassi et al., “Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure,” Hypertension, vol. 32, no. 4, pp. 746–752, 1998. View at Scopus
  13. J. Winaver, A. Hoffman, Z. Abassi, and A. Haramati, “Does the heart's hormone, ANP, help in congestive heart failure?” News in Physiological Sciences, vol. 10, pp. 247–253, 1995.
  14. T. Karram, A. Hoffman, B. Bishara et al., “Induction of cardiac hypertrophy by a controlled reproducible sutureless aortocaval shunt in the mouse,” Journal of Investigative Surgery, vol. 18, no. 6, pp. 325–334, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Garcia and S. Diebold, “Simple, rapid, and effective method of producing aortocaval shunts in the rat,” Cardiovascular Research, vol. 24, no. 5, pp. 430–432, 1990. View at Scopus
  16. M. Huang, M. H. LeBlanc, and R. L. Hester, “Evaluation of the needle technique for producing an arteriovenous fistula,” Journal of Applied Physiology, vol. 77, no. 6, pp. 2907–2911, 1994. View at Scopus
  17. Z. Abassi, B. Francis, J. Wessale, E. Ovcharenko, J. Winaver, and A. Hoffman, “Effects of endothelin receptors ET and ET blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure,” Clinical Science, vol. 103, supplement 48, pp. 245S–248S, 2002. View at Scopus
  18. J. G. Hilton, D. M. Kanter, D. R. Hays, et al., “The effect of acute arteriovenous fistula on renal functions,” The Journal of Clinical Investigation, vol. 34, pp. 732–736, 1955.
  19. I. H. Zucker, A. M. Earle, and J. P. Gilmore, “The mechanism of adaptation of left atrial stretch receptors in dogs with chronic congestive heart failure,” Journal of Clinical Investigation, vol. 60, no. 2, pp. 323–331, 1977. View at Scopus
  20. E. G. Schneider, T. P. Dresser, R. E. Lynch, and F. G. Knox, “Sodium reabsorption by proximal tubule of dogs with experimental heart failure,” The American Journal of Physiology, vol. 220, no. 4, pp. 952–957, 1971. View at Scopus
  21. D. Villarreal, J. O. Davis, R. H. Freeman, J. R. Dietz, and S. F. Echtenkamp, “Effects of indomethacin in conscious dogs with experimental high-output heart failure,” The American Journal of Physiology, vol. 245, no. 6, pp. H942–H946, 1983. View at Scopus
  22. D. Villarreal, R. H. Freeman, and M. W. Brands, “DOCA administration and atrial natriuretic factor in dogs with chronic heart failure,” American Journal of Physiology, vol. 257, no. 3, pp. H739–H745, 1989. View at Scopus
  23. D. Villarreal, R. H. Freeman, and R. A. Johnson, “Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure,” American Journal of Physiology, vol. 262, no. 3, pp. R509–R516, 1992. View at Scopus
  24. D. Villarreal, R. H. Freeman, and R. A. Johnson, “Neurohumoral modulators and sodium balance in experimental heart failure,” American Journal of Physiology, vol. 264, no. 4, pp. H1187–H1193, 1993. View at Scopus
  25. L. B. Laplace, “Observations on the effect of an arteriovenous fistula on the human circulation,” The American Journal of the Medical Sciences, vol. 189, pp. 497–507, 1935.
  26. F. H. Epstein, R. S. Post, and M. Mcdowell, “The effects of an arteriovenous fistula on renal hemodynamics and electrolyte excretion,” The Journal of Clinical Investigation, vol. 32, no. 3, pp. 233–241, 1953. View at Scopus
  27. F. H. Epstein, O. W. Shadle, T. B. Ferguson, and M. E. Mcdowell, “Cardiac output and intracardiac pressures in patients with arteriovenous fistulas,” The Journal of Clinical Investigation, vol. 32, no. 6, pp. 543–547, 1953. View at Scopus
  28. S. F. Flaim, W. J. Minteer, and R. Zelis, “Acute effects of arterio-venous shunt on cardiovascular hemodynamics in rat,” Pflugers Archiv European Journal of Physiology, vol. 385, no. 3, pp. 203–209, 1980. View at Scopus
  29. Z. Liu, D. R. Hilbelink, W. B. Crockett, and A. M. Gerdes, “Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas: 1. Developing and established hypertrophy,” Circulation Research, vol. 69, no. 1, pp. 52–58, 1991. View at Scopus
  30. L. Watkins Jr., J. A. Burton, and E. Haber, “The renin angiotensin aldosterone system in congestive failure in conscious dogs,” Journal of Clinical Investigation, vol. 57, no. 6, pp. 1606–1617, 1976. View at Scopus
  31. F. Pieruzzi, Z. A. Abassi, and H. R. Keiser, “Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure,” Circulation, vol. 92, no. 10, pp. 3105–3112, 1995. View at Scopus
  32. M. Ruzicka, B. Yuan, E. Harmsen, and F. H. H. Leenen, “The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats: effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker,” Circulation, vol. 87, no. 3, pp. 921–930, 1993. View at Scopus
  33. D. Villarreal and R. H. Freeman, “ANF and the renin-angiotensin system in the regulation of sodium balance: longitudinal studies in experimental heart failure,” Journal of Laboratory and Clinical Medicine, vol. 118, no. 6, pp. 515–522, 1991. View at Scopus
  34. M. Packer, “Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure,” American Journal of Kidney Diseases, vol. 10, no. 1, pp. 66–73, 1987. View at Scopus
  35. R. W. Schrier, A. Masoumi, and E. Elhassan, “Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 6, pp. 1132–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. V. J. Dzau, “Renal and circulatory mechanisms in congestive heart failure,” Kidney International, vol. 31, no. 6, pp. 1402–1415, 1987. View at Scopus
  37. Z. A. Abassi, G. Kelly, E. Golomb, H. Klein, and H. R. Keiser, “Losartan improves the natriuretic response to ANF in rats with high- output heart failure,” Journal of Pharmacology and Experimental Therapeutics, vol. 268, no. 1, pp. 224–230, 1994. View at Scopus
  38. R. Willenbrock, M. Scheuermann, G. Thibault et al., “Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt,” Cardiovascular Research, vol. 42, no. 3, pp. 733–742, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. K. L. Skorecki, J. Winaver, and Z. A. Abassi, “Extracellular fluid and edema formation,” in The Kidney, B. M. Brenner, Ed., pp. 398–458, Saunders Elsevier, Philadelphia, Pa, USA, 2008.
  40. M. J. Niebauer, M. J. Holmberg, and I. H. Zucker, “Aortic baroreceptor characteristics in dogs with chronic high output failure,” Basic Research in Cardiology, vol. 81, no. 2, pp. 111–122, 1986. View at Scopus
  41. D. Villarreal, R. H. Freeman, R. A. Johnson, and J. C. Simmons, “Effects of renal denervation on postprandial sodium excretion in experimental heart failure,” American Journal of Physiology, vol. 266, no. 5, pp. R1599–R1604, 1994. View at Scopus
  42. G. L. Robertson, “Physiology of ADH secretion,” Kidney International, vol. 32, no. 21, pp. S20–S26, 1987. View at Scopus
  43. L. Bankir, “Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects,” Cardiovascular Research, vol. 51, no. 3, pp. 372–390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Bishara, H. Shiekh, T. Karram et al., “Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 414–422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. R. Goldsmith, G. S. Francis, and A. W. Cowley, “Increased plasma arginine vasopressin levels in patients with congestive heart failure,” Journal of the American College of Cardiology, vol. 1, no. 6, pp. 1385–1390, 1983. View at Scopus
  46. S. R. Goldsmith and M. Gheorghiade, “Vasopressin antagonism in heart failure,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1785–1791, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. R. W. Schrier, “Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. II,” New England Journal of Medicine, vol. 319, no. 17, pp. 1127–1134, 1988. View at Scopus
  48. P. Y. Martin and R. W. Schrier, “Sodium and water retention in heart failure: pathogenesis and treatment,” Kidney International, Supplement, vol. 51, no. 59, pp. S57–S61, 1997. View at Scopus
  49. M. Gheorghiade, W. A. Gattis, C. M. O'Connor et al., “Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 16, pp. 1963–1971, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Masaki, “Possible role of endothelin in endothelial regulation of vascular tone,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 235–255, 1995. View at Scopus
  51. D. E. Kohan, “The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure,” Current Opinion in Nephrology and Hypertension, vol. 15, no. 1, pp. 34–40, 2006. View at Scopus
  52. E. R. Levin, “Endothelins,” New England Journal of Medicine, vol. 333, no. 6, pp. 356–363, 1995. View at Publisher · View at Google Scholar · View at Scopus
  53. P. M. Vanhoutte, “Endothelium-dependent responses in congestive heart failure,” Journal of Molecular and Cellular Cardiology, vol. 28, no. 11, pp. 2233–2240, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. A. L. Clavell and J. C. Burnett, “Physiologic and pathophysiologic roles of endothelin in the kidney,” Current Opinion in Nephrology and Hypertension, vol. 3, no. 1, pp. 66–72, 1994. View at Scopus
  55. M. P. Love and J. J. V. McMurray, “Endothelin in chronic heart failure: current position and future prospects,” Cardiovascular Research, vol. 31, no. 5, pp. 655–674, 1996. View at Scopus
  56. J. J. McMurray, S. G. Ray, I. Abdullah, H. J. Dargie, and J. J. Morton, “Plasma endothelin in chronic heart failure,” Circulation, vol. 85, no. 4, pp. 1374–1379, 1992. View at Scopus
  57. T. G. Von Lueder, H. Kjekshus, T. Edvardsen et al., “Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1,” Cardiovascular Research, vol. 63, no. 1, pp. 41–50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. L. A. Brown, D. J. Nunez, C. I. O. Brookes, and M. R. Wilkins, “Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat,” Cardiovascular Research, vol. 29, no. 6, pp. 768–774, 1995. View at Publisher · View at Google Scholar · View at Scopus
  59. P. G. Cavero, W. L. Miller, D. M. Heublein, K. B. Margulies, and J. C. Burnett, “Endothelin in experimental congestive heart failure in the anesthetized dog,” American Journal of Physiology, vol. 259, no. 2, pp. F312–F317, 1990. View at Scopus
  60. G. Boerrigter and J. C. Burnett, “Recent advances in natriuretic peptides in congestive heart failure,” Expert Opinion on Investigational Drugs, vol. 13, no. 6, pp. 643–652, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. R. R. Brandt, R. S. Wright, M. M. Redfield, and J. C. Burnett, “Atrial natriuretic peptide in heart failure,” Journal of the American College of Cardiology, vol. 22, no. 4, pp. 86A–92A, 1993. View at Scopus
  62. A. Hoffman, J. C. Burnett, A. Haramati, and J. Winaver, “Effects of atrial natriuretic factor in rats with experimental high-output heart failure,” Kidney International, vol. 33, no. 3, pp. 656–661, 1988. View at Scopus
  63. D. Villarreal, R. H. Freeman, and R. A. Johnson, “Renal effects of ANF (95-126), a new atrial peptide analogue, in dogs with experimental heart failure,” American Journal of Hypertension, vol. 4, no. 6, pp. 508–515, 1991. View at Scopus
  64. R. Willenbrock, I. Pagel, M. Scheuermann et al., “Renal function in high-output heart failure in rats: role of endogenous natriuretic peptides,” Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 572–580, 1999. View at Scopus
  65. J. C. Burnett Jr., P. C. Kao, and D. C. Hu, “Atrial natriuretic peptide elevation in congestive heart failure in the human,” Science, vol. 231, no. 4742, pp. 1145–1147, 1986.
  66. G. A. J. Riegger, D. Elsner, E. P. Kromer et al., “Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects,” Circulation, vol. 77, no. 2, pp. 398–406, 1988. View at Scopus
  67. M. E. Lee, W. L. Miller, B. S. Edwards, and J. C. Burnett, “Role of endogenous atrial natriuretic factor in acute congestive heart failure,” Journal of Clinical Investigation, vol. 84, no. 6, pp. 1962–1966, 1989. View at Scopus
  68. H. Yechieli, L. Kahana, A. Haramati, A. Hoffman, and J. Winaver, “Regulation of renal glomerular and papillary ANP receptors in rats with experimental heart failure,” American Journal of Physiology, vol. 265, no. 1, pp. F119–F125, 1993. View at Scopus
  69. Z. Abassi, J. C. Burnett, E. Grushka, A. Hoffman, A. Haramati, and J. Winaver, “Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure,” American Journal of Physiology, vol. 261, no. 4, pp. R858–R864, 1991. View at Scopus
  70. J. B. Smith and T. M. Lincoln, “Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor,” American Journal of Physiology, vol. 253, no. 1, pp. C147–C150, 1987. View at Scopus
  71. R. Corti, J. C. Burnett Jr., J. L. Rouleau, F. Ruschitzka, and T. F. Lüscher, “Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?” Circulation, vol. 104, no. 15, pp. 1856–1862, 2001. View at Scopus
  72. Z. A. Abassi, A. Yahia, S. Zeid et al., “Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure,” American Journal of Physiology, vol. 288, no. 2, pp. H722–H728, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. M. R. Wilkins, S. L. Settle, P. T. Stockmann, and P. Needleman, “Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 16, pp. 6465–6469, 1990. View at Publisher · View at Google Scholar · View at Scopus
  74. S. D. Katz, “Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure,” Congestive Heart Failure, vol. 9, no. 1, pp. 9–15, 2003. View at Scopus
  75. H. H. Chen, B. K. Huntley, J. A. Schirger, A. Cataliotti, and J. C. Burnett, “Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure,” Journal of the American Society of Nephrology, vol. 17, no. 10, pp. 2742–2747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. A. C. Barger, F. P. Muldowney, and M. R. Liebowitz, “Role of the kidney in the pathogenesis of congestive heart failure,” Circulation, vol. 20, pp. 273–285, 1959.
  77. I. Ichikawa, T. Yoshioka, A. Fogo, and V. Kon, “Role of angiotensin II in altered glomerular hemodynamics in congestive heart failure,” Kidney International, vol. 38, no. 30, pp. S123–S126, 1990. View at Scopus
  78. A. Lerman, S. H. Kubo, L. K. Tschumperlin, and J. C. Burnett, “Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation,” Journal of the American College of Cardiology, vol. 20, no. 4, pp. 849–853, 1992. View at Scopus
  79. Z. Abassi, J. Winaver, I. Rubinstein et al., “Renal endothelin-converting enzyme in rats with congestive heart failure,” Journal of Cardiovascular Pharmacology, vol. 31, supplement 1, pp. S31–S34, 1998. View at Scopus
  80. Z. Abassi, K. Gurbanov, I. Rubinstein, O. S. Better, A. Hoffman, and J. Winaver, “Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide,” American Journal of Physiology, vol. 274, no. 4, pp. F766–F774, 1998. View at Scopus
  81. B. N. Francis, Z. Abassi, S. Heyman, J. Winaver, and A. Hoffman, “Differential regulation of ET(A) and ET(B) in the renal tissue of rats with compensated and decompensated heart failure,” Journal of Cardiovascular Pharmacology, vol. 44, supplement 1, pp. S362–S365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Francis, J. Winaver, T. Karram, A. Hoffman, and Z. Abassi, “Renal and systemic effects of chronic blockade of ET(A) or ET(B) in normal rats and animals with experimental heart failure,” Journal of Cardiovascular Pharmacology, vol. 44, supplement 1, pp. S54–S58, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. P. I. Anand, P. J. McMurray, P. J. N. Cohn et al., “Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 364, no. 9431, pp. 347–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. R. F. Furchgott and J. V. Zawadzki, “The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine,” Nature, vol. 288, no. 5789, pp. 373–376, 1980. View at Scopus
  85. Z. Abassi, S. Brodsky, O. Gealekman, I. Rubinstein, A. Hoffman, and J. Winaver, “Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure,” American Journal of Physiology, vol. 280, no. 1, pp. F43–F53, 2001. View at Scopus
  86. R. A. Mulinari, I. Gavras, Y. X. Wang, R. Franco, and H. Gavras, “Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction,” Circulation, vol. 81, no. 1, pp. 308–311, 1990. View at Scopus
  87. S. E. Ishikawa and R. W. Schrier, “Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion,” Clinical Endocrinology, vol. 58, no. 1, pp. 1–17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Ishikawa, T. Saito, and K. Okada, “Effect of vasopressin antagonist on water excretion in inferior vena cava constriction,” Kidney International, vol. 30, no. 1, pp. 49–55, 1986. View at Scopus
  89. M. Naitoh, H. Suzuki, M. Murakami et al., “Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs,” American Journal of Physiology, vol. 267, no. 6, pp. H2245–H2254, 1994. View at Scopus
  90. J. G. Verbalis, “Vasopressin V2 receptor antagonists,” Journal of Molecular Endocrinology, vol. 29, no. 1, pp. 1–9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. D. L. Xu, P. Y. Martin, M. Ohara et al., “Upregulation of aquaporin-2 water channel expression in chronic heart failure rat,” Journal of Clinical Investigation, vol. 99, no. 7, pp. 1500–1505, 1997. View at Scopus
  92. J. K. Kim, J. B. Michel, F. Soubrier, J. Durr, P. Corvol, and R. W. Schrier, “Arginine vasopressin gene expression in chronic cardiac failure in rats,” Kidney International, vol. 38, no. 5, pp. 818–822, 1990. View at Scopus
  93. P. R. Kalra, S. D. Anker, and A. J. S. Coats, “Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin,” Cardiovascular Research, vol. 51, no. 3, pp. 495–509, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Gheorghiade, I. Niazi, J. Ouyang et al., “Vasopressin V-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial,” Circulation, vol. 107, no. 21, pp. 2690–2696, 2003. View at Scopus
  95. F. Wong, A. T. Blei, L. M. Blendis, and P. J. Thuluvath, “A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial,” Hepatology, vol. 37, no. 1, pp. 182–191, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. C. R. Lee, M. L. Watkins, J. H. Patterson et al., “Vasopressin: a new target for the treatment of heart failure,” American Heart Journal, vol. 146, no. 1, pp. 9–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. G. De Simone, R. McClelland, J. S. Gottdiener, A. Celentano, R. A. Kronmal, and J. M. Gardin, “Relation of hemodynamics and risk factors to ventricular-vascular interactions in the elderly: the cardiovascular health study,” Journal of Hypertension, vol. 19, no. 10, pp. 1893–1903, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. B. H. Lorell, “Transition from hypertrophy to failure,” Circulation, vol. 96, no. 11, pp. 3824–3827, 1997. View at Scopus
  99. K. W. Saupe, C. C. Lim, J. S. Ingwall, C. S. Apstein, and F. R. Eberli, “Comparison of hearts with 2 types of pressure-overload left ventricular hypertrophy,” Hypertension, vol. 35, no. 5, pp. 1167–1172, 2000. View at Scopus
  100. F. Z. Meerson, M. G. Pshennikova, and I. YU. Malyshev, “Adaptive defense of the organism. Architecture of the structural trace and cross protective effects of adaptation,” Annals of the New York Academy of Sciences, vol. 793, pp. 371–385, 1996. View at Scopus
  101. G. T. Schuyler and L. R. Yarbrough, “Changes in myosin and creatine kinase mRNA levels with cardiac hypertrophy and hypothyroidism,” Basic Research in Cardiology, vol. 85, no. 5, pp. 481–494, 1990. View at Scopus
  102. H. G. Zimmer, C. Kolbeck-Ruhmkorff, and W. Zierhut, “Cardiac hypertrophy induced by α- and β-adrenergic receptor stimulation,” Cardioscience, vol. 6, no. 1, pp. 47–57, 1995.
  103. D. Greenen, P. Buttrick, and J. Scheuer, “Cardiovascular and hormonal responses to swimming and running in the rat,” Journal of Applied Physiology, vol. 65, no. 1, pp. 116–123, 1988. View at Scopus
  104. D. Laurent, P. R. Allegrini, and W. Zierhut, “Different left ventricular remodelling and function in two models of pressure overload as assessed in vivo by magnetic resonance imaging,” Journal of Hypertension, vol. 13, no. 6, pp. 693–700, 1995. View at Publisher · View at Google Scholar
  105. K. R. Chien, “Stress pathways and heart failure,” Cell, vol. 98, no. 5, pp. 555–558, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. B. Swynghedauw and C. Baillard, “Biology of hypertensive cardiopathy,” Current Opinion in Cardiology, vol. 15, no. 4, pp. 247–253, 2000. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Bader, “Rat models of cardiovascular diseases,” Methods in Molecular Biology, vol. 597, pp. 403–414, 2010. View at Scopus
  108. E. Monnet and J. C. Chachques, “Animal models of heart failure: what is new?” Annals of Thoracic Surgery, vol. 79, no. 4, pp. 1445–1453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. R. D. Patten and M. R. Hall-Porter, “Small animal models of heart failure: development of novel therapies, past and present,” Circulation: Heart Failure, vol. 2, no. 2, pp. 138–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. S. F. Flaim, W. J. Minteer, S. H. Nellis, and D. P. Clark, “Chronic arteriovenous shunt: evaluation of a model for heart failure in rat,” The American Journal of Physiology, vol. 236, no. 5, pp. H698–H704, 1979. View at Scopus
  111. A. Calderone, N. Takahashi, N. J. Izzo, C. M. Thaik, and W. S. Colucci, “Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs,” Circulation, vol. 92, no. 9, pp. 2385–2390, 1995. View at Scopus
  112. L. H. Opie, P. J. Commerford, B. J. Gersh, and M. A. Pfeffer, “Controversies in ventricular remodelling,” The Lancet, vol. 367, no. 9507, pp. 356–367, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. B. A. Carabello, “Concentric versus eccentric remodeling,” Journal of Cardiac Failure, vol. 8, no. 6, pp. S258–S263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Mihl, W. R. M. Dassen, and H. Kuipers, “Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletes,” Netherlands Heart Journal, vol. 16, no. 4, pp. 129–133, 2008. View at Scopus
  115. B. A. Carabello, “Models of volume overload hypertrophy,” Journal of Cardiac Failure, vol. 2, no. 1, pp. 55–64, 1996. View at Scopus
  116. J. N. Cohn, R. Ferrari, and N. Sharpe, “Cardiac remodeling-concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling,” Journal of the American College of Cardiology, vol. 35, no. 3, pp. 569–582, 2000. View at Publisher · View at Google Scholar · View at Scopus
  117. P. Lijnen and V. Petrov, “Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes,” Journal of Molecular and Cellular Cardiology, vol. 31, no. 5, pp. 949–970, 1999. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Yamazaki and Y. Yazaki, “Molecular basis of cardiac hypertrophy,” Zeitschrift fur Kardiologie, vol. 89, no. 1, pp. 1–6, 2000. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Packer, “The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure,” Journal of the American College of Cardiology, vol. 20, no. 1, pp. 248–254, 1992. View at Scopus
  120. A. M. Katz, “Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses,” Journal of Cellular and Molecular Medicine, vol. 7, no. 1, pp. 1–10, 2003. View at Scopus
  121. G. Suzuki, H. Morita, T. Mishima et al., “Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure,” Circulation, vol. 106, no. 23, pp. 2967–2972, 2002. View at Publisher · View at Google Scholar · View at Scopus
  122. J. A. Delyani, E. L. Robinson, and A. E. Rudolph, “Effect of a selective aldosterone receptor antagonist in myocardial infarction,” American Journal of Physiology, vol. 281, no. 2, pp. H647–H654, 2001. View at Scopus
  123. A. E. G. Raine, P. Erne, and E. Burgisser, “Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure,” New England Journal of Medicine, vol. 315, no. 9, pp. 533–537, 1986.
  124. Y. Shenker, R. S. Sider, E. A. Ostafin, and R. J. Grekin, “Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema,” Journal of Clinical Investigation, vol. 76, no. 4, pp. 1684–1687, 1985. View at Scopus
  125. R. J. Rodeheffer, I. Tanaka, T. Imada, A. S. Hollister, D. Robertson, and T. Inagami, “Atrial pressure and secretion of atrial natriuretic factor into the human central circulation,” Journal of the American College of Cardiology, vol. 8, no. 1, pp. 18–26, 1986.
  126. A. S. Maisel, J. Koon, P. Krishnaswamy et al., “Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction,” American Heart Journal, vol. 141, no. 3, pp. 367–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. H. H. Chen and J. C. Burnett Jr., “The natriuretic peptides in heart failure: diagnostic and therapeutic potentials,” Proceedings of the Association of American Physicians, vol. 111, no. 5, pp. 406–416, 1999. View at Scopus
  128. G. M. Bialik, Z. A. Abassi, I. Hammel, J. Winaver, and D. Lewinson, “Evaluation of atrial natriuretic peptide and brain natriuretic peptide in atrial granules of rats with experimental congestive heart failure,” Journal of Histochemistry and Cytochemistry, vol. 49, no. 10, pp. 1293–1300, 2001. View at Scopus
  129. G. L. Brower, J. R. Henegar, and J. S. Janicki, “Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload,” American Journal of Physiology, vol. 271, no. 5, pp. H2071–H2078, 1996. View at Scopus
  130. M. Huang, R. L. Hester, and A. C. Guyton, “Hemodynamic changes in rats after opening an arteriovenous fistula,” American Journal of Physiology, vol. 262, no. 3, pp. H846–H851, 1992. View at Scopus
  131. G. L. Brower and J. S. Janicki, “Contribution of ventricular remodeling to pathogenesis of heart failure in rats,” American Journal of Physiology, vol. 280, no. 2, pp. H674–H683, 2001. View at Scopus
  132. X. Wang, B. Ren, S. Liu, E. Sentex, P. S. Tappia, and N. S. Dhalla, “Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat,” Journal of Applied Physiology, vol. 94, no. 2, pp. 752–763, 2003. View at Scopus
  133. M. H. Humphreys, H. Al-Bander, J. F. Eneas, and M. Schambelan, “Factors determining electrolyte excretion and renin secretion after closure of an arteriovenous fistula in the dog,” Journal of Laboratory and Clinical Medicine, vol. 98, no. 1, pp. 89–98, 1981. View at Scopus
  134. A. Hoffman, J. Winaver, and A. Haramati, “Atrial natriuretic peptide in the recovery from high-output congestive heart failure,” American Journal of Medicine, vol. 88, no. 5, p. 547, 1990. View at Scopus
  135. J. J. Alexander and A. L. Imbembo, “Aorta-vena cava fistula,” Surgery, vol. 105, no. 1, pp. 1–12, 1989. View at Scopus
  136. I. H. Zucker, A. M. Earle, and J. P. Gilmore, “Changes in the sensitivity of left atrial receptors following reversal of heart failure,” The American Journal of Physiology, vol. 237, no. 5, pp. H555–H559, 1979. View at Scopus